BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DZD6008 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DZD6008\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07070440-2251@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:DZD6008: Phase 1/2 readout est. (NCT07070440)
DESCRIPTION:DZD6008\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: DZD60
 08 Combination Therapy in Patients With Locally Advanced or Metastatic NSC
 LC With EGFR Mutation (TIAN-SHAN7)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dzd6008#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07070440
URL:https://assetmemo.bio/drug/dzd6008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905197-2251@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:DZD6008: Phase 1 readout est. (NCT06905197)
DESCRIPTION:DZD6008\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Multi
 national Study Assessing an Oral EGFR Inhibitor\, DZD6008 in Patients Who 
 Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)\nEstimated primary co
 mpletion: September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dzd6008#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06905197
URL:https://assetmemo.bio/drug/dzd6008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813365-2251@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:DZD6008: Phase 1 readout est. (NCT06813365)
DESCRIPTION:DZD6008\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Assessi
 ng an Oral EGFR Inhibitor\, DZD6008 in Patients Who Have Advanced NSCLC Wi
 th EGFR Mutations (TIAN-SHAN2)\nEstimated primary completion: 30 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dzd6008#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06813365
URL:https://assetmemo.bio/drug/dzd6008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079475-2251@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:DZD6008: Phase 1/2 readout est. (NCT07079475)
DESCRIPTION:DZD6008\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Wh
 o Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)\nEstimated primary 
 completion: June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dzd6008#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07079475
URL:https://assetmemo.bio/drug/dzd6008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
